Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

IDYA stock hub

IDEAYA Biosciences, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

IDYAis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

2.5B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

IDYA

In the news

Latest news · IDYA

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-14.3

P25 -105.6P50 -46.5P75 -3.1

ROIC-11.4

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All IDYA market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

204

Groups with data

Currency

USD

Showing 204 of 204 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001676725
Company name	IDEAYA Biosciences, Inc.
Country	United States
Country code	US
Cusip	45166A102
Employees	145
Employees Change	14%
Employees Change Percent	10.69
Enterprise value	$1.5B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2019-05-23
Isin	US45166A1025
Last refreshed	2026-05-10
Market cap	$2.5B
Market cap category	Mid-Cap
Price	$28.32
Price currency	USD
Rev Per Employee	1,553,586.21x
Sector	Healthcare
Sic	2834
Symbol	IDYA
Website	https://www.ideayabio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-5.63%
EV Sales Forward	26.5x
EV/Sales	6.85x
FCF yield	-3.53%
P/B ratio	2.65x
P/S ratio	11.05x
PS Forward	42.71x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-81.44%
EBITDA Margin	-80.21%
Gross margin	-50.73%
Gross Profit	$-114.3M
Net Income	$-140.1M
Net Income Growth Years	1%
Pretax Margin	-62.17%
Profit Margin	-62.17%
Profit Per Employee	$-965,924
ROA	-10.76
Roa5y	-13.51
ROCE	-19
ROE	-14.28
Roe5y	-20.96
ROIC	-11.38

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	58.88%
Cagr3y	14.09%
Cagr5y	8.11%
EPS Growth Years	1
Revenue Growth	3,118.14x
Revenue Growth Years	1x
Revenue Growth3 Y	68.07x
Revenue Growth5 Y	53.1x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.21
Assets	$1B
Cash	$671.2M
Current Assets	$696.1M
Current Liabilities	$64.8M
Debt	$28.6M
Debt Equity	$0.03
Equity	$937.3M
Liabilities	$93.1M
Long Term Assets	$334.2M
Long Term Liabilities	$28.3M
Net Cash	$944.3M
Net Cash By Market Cap	$37.95
Net Cash Growth	-7.89%
Net Debt Equity	$-1.01
Tangible Book Value	$937.3M
Tangible Book Value Per Share	$10.67
WACC	3.96

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	10.74
Net Working Capital	$-39.6M
Quick ratio	10.45
Working Capital	$631.3M
Working Capital Turnover	$0.35

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-4.21%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	58.83%
200-day SMA	30.56
3Y total return	48.51%
50-day SMA	31.78
50-day SMA vs 200-day SMA	50over200
5Y total return	47.65%
All Time High	47.74
All Time High Change	-40.67%
All Time High Date	2024-02-15
All Time Low	2.95
All Time Low Change	860%
All Time Low Date	2020-03-17
ATR	1.45
Beta	-0.04
Beta1y	0.89
Beta2y	1.37
Ch YTD	-18.08
High	28.64
High52	39.28
High52 Date	2026-01-07
High52ch	-27.9%
Low	28.01
Low52	16.84
Low52 Date	2025-05-14
Low52ch	68.17%
Ma50ch	-10.88%
Premarket Change Percent	0.5
Premarket Price	$28.38
Premarket Volume	662
Price vs 200-day SMA	-7.32%
RSI	38.13
RSI Monthly	49.47
RSI Weekly	42.96
Sharpe ratio	1.13x
Sortino ratio	1.9
Total Return	-4.21%
Tr YTD	-18.08
Tr1m	-8.38%
Tr1w	0.46%
Tr3m	-11.97%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	16
Analyst Count Top	7
Analyst Price Target Top	$53.43
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-1
Earnings Revenue Estimate	6,068,704x
Operating Income	$-183.5M
Operating margin	-81.44
Price target	$53.14
Price Target Change	$87.64
Price Target Change Top	$88.67

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	87,007,943%
Float Percent	99.03%
Shares Insiders	0.97%
Shares Institutions	109.94%
Shares Out	87,860,920
Shares Qo Q	0.13%
Shares Yo Y	4.21%
Short Float	12.14%
Short Ratio	6.32
Short Shares	12.02

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-138.3M
Average Volume	1,630,869.15x
Bv Per Share	10.67
CAPEX	$-2M
Ch1m	-8.38
Ch1w	0.46
Ch1y	58.83
Ch3m	-11.97
Ch3y	48.51
Ch5y	47.65
Ch6m	-6.35
Change	0.28%
Change From Open	0.43
Close	28.24
Days Gap	-0.14
Depreciation Amortization	2,788,000
Dollar Volume	15,456,008.2
Earnings Date	2026-05-05
Earnings Time	bmo
EBIT	$-183.5M
EBITDA	$-180.7M
EPS	$-1.58
F Score	3
FCF	$-87.9M
FCF EV Yield	-5.7x
FCF Per Share	$-1
Financing CF	4,817,000
Fiscal Year End	December
Founded	2,015
Investing CF	109,111,000
Ipr	183.2
Iprfo	102.3
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-05
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-17
Ma150	32.42
Ma150ch	-12.64%
Ma20	30.46
Ma20ch	-7.02%
Net CF	28,002,000
Next Earnings Date	2026-08-04
Open	28.2
Optionable	Yes
Position In Range	49.21
Post Close	28.32
Postmarket Change Percent	-0.99
Postmarket Price	$28.04
Ppne	31,247,000
Pre Close	28.24
Price Date	2026-05-08
Ptbv Ratio	2.65
Relative Volume	0.33x
Revenue	225,270,000x
SBC By Revenue	22.38x
Share Based Comp	50,414,000
Tr6m	-6.35%
Us State	California
Volume	545,763
Z Score	14.59

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does IDYA pay a dividend?

Capital-return profile for this ticker.

Performance

IDYA stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns IDYA?

Insider, institutional, and short-interest positioning.

Institutional ownership

+109.9%

Float: +99.0% of shares outstanding

Insider ownership

+1.0%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

IDYA momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

38.1

Neutral momentum band

Price vs 200-day MA

-7.3%

50/200-day relationship not available

Beta (5Y)

-0.04

Less volatile than the market

Sharpe ratio

1.13

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About IDYA

Hub-level FAQ points readers to the deeper analysis pages.

What is the current IDYA stock rating?

IDEAYA Biosciences, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full IDYA analysis?

The full report lives at /stocks/IDYA/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for IDYA?

The latest report frames IDYA around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the IDYA page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.